Clinical Trials

Inclusion Criteria:

• Diagnosis of Fibrillary Glomerulonephritis
• Proteinuria > 1 gram
• Patients need to be treated with an ACEi and/or ARB, for at least 3 months prior to enrollment
• BP< 140/90 mmHg in >75% of readings
• Women must be post menopausal, surgically sterile, or practicing a medically approved method of contraception
• Able and willing to give written informed consent and comply with the requirements of the study protocol
• eGFR greater than or equal to 25 mL/ min using CKD EPI formula or a quantified creatinine clearance > 25mL/ min and/or serum creatinine <3.0 mg/dL
• Negative chest x-ray within one year
• Negative serum pregnancy test for women of child bearing age
• Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for 12 months after completion of treatment
• Total bilirubin, AST, ALT, and alkaline phosphatase levels <2 times the upper limit of normal
• Hemoglobin >7.0 gm/dL, white count >3.0 X 10(9), platelet count >100 X 10(9)

Exclusion Criteria:

• History of HIV
• Presence of active infection
• New York Hear Association Classification III or IV heart disease
• Concomitant malignancies or previous malignancies within the last 5 years
• History of psychiatric disorder
• At the Investigator's discretion, receipt of a live vaccine within 4 weeks prior to treatment
• Positive hepatitis B or C serology is considered a potential exclusion criterion. For inclusion into the study, the patient must have a negative HBsAg and anti-HBc lab value within 1 year of signing consent.